BIOMARCADORES PARA DIAGNÓSTICO DE DEMENCIA

VolverVolver

Resultados 44 resultados LastUpdate Última actualización 22/05/2019 [17:15:00] pdf PDF

Solicitudes publicadas en los últimos 60 días / Applications published in the last 60 days

Página1 de 2 nextPage   por página


ANTIBODIES AND ANTIGEN-BINDING FRAGMENTS THAT SPECIFICALLY BIND TO MICROTUBULE-ASSOCIATED PROTEIN TAU

NºPublicación: EP3486256A2 22/05/2019

Solicitante:

JANSSEN VACCINES & PREVENTION BV [NL]

CN_107074935_A

Resumen de: EP3486256A2

The invention relates to antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau. The invention also relates to diagnostic, prophylactic and therapeutic methods using anti-tau antibodies.

traducir

ANTIBODIES SPECIFIC FOR HYPERPHOSPHORYLATED TAU AND METHODS OF USE THEREOF

NºPublicación: EP3484916A1 22/05/2019

Solicitante:

H LUNDBECK AS [DK]

CN_109618556_A

Resumen de: WO2018011073A1

The present invention relates to a class of monoclonal antibody that specifically binds the phosphorylated serine 396 residue on pathological hyperphosphorylated (PHF) tau (pS396) with improved affinity, as well as to methods of using these molecules and their tau binding fragments in the treatment of Alzheimer s disease and other tauopathies.

traducir

METHODS AND SYSTEM FOR DETECTING LIVING, NON-DEMENTED PATIENTS WHO HAVE ALZHEIMER'S DISEASE NEUROPATHOLOGY FOR ALZHEIMER'S DISEASE

NºPublicación: US2019142329A1 16/05/2019

Solicitante:

INSPIRED LIFE MEDICAL INC [US]

US_2019142326_A1

Resumen de: US2019142329A1

The present method is directed to determining whether a living, non-demented patient with Alzheimer's neuropathology, i.e., significant levels of amyloid plaque in the brain, is within the early pre-clinical stages of Alzheimer's disease. In turn, if the living, non-demented patient with Alzheimer's neuropathology is determined to not be in the early stages of Alzheimer's disease, then it may be concluded that the patient has at least a resistance to Alzheimer's disease neuropathology, and perhaps an immunity thereto, wherein the amyloid plaque does not localize to the patient's brain synapses, thereby preserving cognitive ability. A 3-step method comprising (1) conducting a cognitive test; (2) detecting brain plaque levels; and (3) conducting a bi-lateral olfactory sensitivity test using pure odorants is therefore provided.

traducir

Aß Modulating Peptides

NºPublicación: AU2019200832A1 16/05/2019

Solicitante:

NEUROSCIENTIFIC BIOPHARMACEUTICALS LTD

US_2016244486_A1

Resumen de: AU2019200832A1

Abstract The present invention relates to an AP modulating peptide comprising a peptide selected from the list of peptides comprising: (i) Arg-Lys-Leu-Met-Gln-Pro-Thr-Arg-Asn (SEQ ID NO:1); (ii) Arg-Lys-Leu-Met-Gln-Pro-Thr-Arg-Asn-Arg-Arg-Asn-Pro-Asn-Thr (SEQ ID NO:2); (iii) a peptide according to (i) or (ii) wherein at least one of the amino acids is a D-amino acid; (iv) a functional variant of a peptide according to any one of (i) to (iii); and (v) a peptide consisting of at least 3-5 contiguous amino acid residues of a peptide according to (i), (ii), (iii) or (iv). The present invention also relates to an AP modulating peptide comprising SEQ ID NO: 2 wherein all of the amino acids are D-amino acids. FigureI1A 140 AP42 only 1 350 W6 Af:Scr9mer 1:20 2M Af:l5mer S.A. 1:20 0 6000 12000 18000 24000 30000 lime (sec) Figurel1B -A42 only c -in+Scr o 9mer 300 1:20 _ -4-- ~250 1:20 a) -+15mer 2-00 S.A. 1:20 >l 150 0 5000 10000 15000 20000 TIME [sec]

traducir

Antibodies to pyroglutamate amyloid-ß and uses thereof

NºPublicación: AU2017355596A1 16/05/2019

Solicitante:

JANSSEN PHARMACEUTICA NV

TW_201827467_A

Resumen de: AU2017355596A1

The invention provides an antibody or antigen binding fragments thereof that binds to 3pE Aβ and methods of making and using the antibody or antigen binding fragment thereof, including use for formulations, administration and kits. The antibody and antigen binding fragments thereof and methods disclosed are useful for diagnosis, prognosis and treatment of Alzheimer's disease or other β-amyloid-related diseases.

traducir

DEVICES, SYSTEMS AND METHODS FOR TESTING OLFACTORY SENSITIVITY

NºPublicación: US2019142326A1 16/05/2019

Solicitante:

INSPIRED LIFE MEDICAL INC [US]

US_2019142329_A1

Resumen de: US2019142326A1

The present system is directed in various embodiments to devices and methods for testing a patient's olfactory capability and/or sensitivity. The devices and methods may be used to test and compare a patient's ability to detect and/or identify an aroma or odorant presented to each nostril. Alternatively, the devices and methods may be used to generally assess, without regard to nostril-to-nostril comparative results, a patient's olfactory ability. The device may comprise a disk that comprises a plurality of odorant compartments that may be progressively advanced as the testing for a subject odorant is completed. The device may comprise a passive airway and an active airway, wherein only one nostril receives aroma-infused air while the other nostril receives atmospheric air. In other cases, the device may present aroma-infused air to both nostrils at the same time.

traducir

Immunoglobulins Directed to Bacterial, Viral and ENDOGENOUS Polypetides

NºPublicación: US2019144528A1 16/05/2019

Solicitante:

COVALENT BIOSCIENCE INCORPORATED [US]

US_2010183614_A1

Resumen de: US2019144528A1

Disclosed are antibodies (immunoglobulins) and fragments thereof that hydrolyze or bind polypeptide antigens belonging to Staphylococcus aureus, hepatitis C virus, human immunodeficiency virus and Alzheimer's disease. Also disclosed are novel methods to improve the antigen reactivity of the immunoglobulins and to treat a pathophysiological condition using the immunoglobulins as therapeutics.

traducir

TREATMENT OF ALZHEIMER'S DISEASE SUBPOPULATIONS WITH POOLED IMMUNOGLOBULIN G

NºPublicación: US2019144530A1 16/05/2019

Solicitante:

BAXALTA INC [US]
BAXALTA GMBH [CH]

AU_2019202459_A1

Resumen de: US2019144530A1

The present invention provides, among other aspects, methods for the treatment of Alzheimer's disease in a subject in need thereof, the method including administration of a therapeutically effective amount of a pooled human immunoglobulin G (IgG) composition to a subject with moderately severe Alzheimer's disease, a subject carrying an ApoE4 allele, or both, where the amount of pooled human IgG is from 300 mg/kg to 800 mg/kg body weight of the subject per two week period, and where the amount is administered in one or more doses during the two week period after initiation of a therapeutic regimen. Also provided, are methods for selecting a treatment regimen for a subject with Alzheimer's disease, including diagnosing the severity of the Alzheimer's disease, determining if the subject carries an APOE4 allele, or both, and assigning a treatment regimen including administration of pooled human immunoglobulin G and/or an anti-beta amyloid monoclonal antibody.

traducir

FKBP52-TAU INTERACTION AS A NOVEL THERAPEUTICAL TARGET FOR TREATING THE NEUROLOGICAL DISORDERS INVOLVING TAU DYSFUNCTION

NºPublicación: JP2019069980A 09/05/2019

Solicitante:

\u30A2\u30F3\u30B9\u30C6\u30A3\u30C1\u30E5 \u30CA\u30B7\u30E7\u30CA\u30EB \u30C9\u30A5 \u30E9 \u30B5\u30F3\u30C6 \u30A8 \u30C9\u30A5 \u30E9 \u30EB\u30B7\u30A7\u30EB\u30B7\u30E5 \u30E1\u30C7\u30A3\u30AB\u30EB

US_2018161432_A1

Resumen de: WO2011045166A1

The invention relates generally to neuroprotection and repair in neurological disorders involving Tau dysfunction (including Alzheimer's disease). The invention describes AND INCLUDES a direct interaction between proteins FKBP52 and Tau. More particularly, the invention relates to a method for screening a drug for the prevention and treatment of neurological disorders involving Tau dysfunction comprising the following steps: a) determining the ability of a candidate compound, to modulate the interaction between a Tau polypeptide and a FKBP52 polypeptide and b) selecting positively the candidate compound that modulates said interaction. The present invention finally relates to diagnostic, prognostic, and monitoring assays of neurological disorders involving Tau dysfunction.

traducir

EVALUATING METHOD FOR FUTURE RISK OF DEVELOPING ALZHEIMER'S DISEASE

NºPublicación: US2019137516A1 09/05/2019

Solicitante:

AJINOMOTO KK [JP]

JP_WO2018008763_A1

Resumen de: US2019137516A1

An evaluating method includes an evaluating step of evaluating future risk of developing Alzheimer's disease for a subject to be evaluated having mild cognitive impairment using a concentration value of at least one of α-ABA, Ala, Arg, Asn, Cit, Gln, Glu, Gly, His, Ile, Leu, Lys, Met, Orn, Phe, Pro, Ser, Thr, Trp, Tyr, Val, Cysteine, Taurine, bABA, Ethylglycine, Hypotaurine, 3-Me-His, 5-HydroxyTrp, aAiBA, and N8-Acetylspermidine in blood of the subject.

traducir

METHODS FOR ESTIMATING MISFOLDED PROTEIN CONCENTRATION IN FLUIDS AND TISSUE BY QUANTITATIVE PMCA

NºPublicación: US2019137515A1 09/05/2019

Solicitante:

AMPRION INC [US]
UNIV TEXAS [US]

Resumen de: US2019137515A1

Described are methods for estimating misfolded protein concentration in fluids and tissues by quantitative PMCA.

traducir

BIOMARKERS AND DIFFERENTIAL DIAGNOSIS OF ALZHEIMER'S DISEASE AND OTHER NEURODEGENERATIVE DISORDERS

NºPublicación: US2019137517A1 09/05/2019

Solicitante:

NANOSOMIX INC [US]

US_2016363599_A1

Resumen de: US2019137517A1

The present invention relates to biomarkers and diagnostic and prognostic methods for Alzheimer's disease and other neurodegenerative disorders. The invention also provides compositions for detecting the biomarker as well as compositions and methods useful for treating Alzheimer's disease and other neurodegenerative disorders.

traducir

NON-INVASIVE IMAGING METHOD FOR EARLY DETECTION AND MAPPING THE SEVERITY OF DISEASES BY USING CEST MRI

NºPublicación: US2019128981A1 02/05/2019

Solicitante:

ALGBURI ISHTAR FAISAL [CA]
NORTH AMERICA IMAGING DEV LLC [US]

WO_2019084520_A1

Resumen de: US2019128981A1

A non-invasive CEST MRI imaging method is disclosed for early detection and mapping the severity of diseases by using MRI. The endogenous magnetic resonance image (MRI) contrast of the biological tissue can rely on the endogenous protons of the proteins and peptides as a source of the contrast, such as hydroxyl, amine, and amide protons, and thereby provide imaging of the accumulation of amyloid beta, accumulation of neurofibrillary tangles, aggregation proteins and peptides, the hypoxia in cancer and non-cancer tissue, the tissues atrophy, distinguish the edema from the tumor, determine tumor boundary, monitor response of tumor to treatment and detect lower grade tumor by using endogenous protons contrast via CEST MRI. The difference in CEST images signals is used to detect and map severity of the diseases and predict response to treatment. The method works without contrast agents or tracers.

traducir

TREATMENT OF ALZHEIMER'S DISEASE SUBPOPULATIONS WITH POOLED IMMUNOGLOBULIN G

NºPublicación: AU2019202459A1 02/05/2019

Solicitante:

BAXALTA INC
BAXALTA GMBH

US_2019144530_A1

Resumen de: AU2019202459A1

The present invention provides, among other aspects, methods for the treatment of Alzheimer's disease in a subject in need thereof, the method including administration of a therapeutically effective amount of a pooled human immunoglobulin G (IgG) composition to a subject with moderately severe Alzheimer's disease, a subject carrying an ApoE4 allele, or both, where the amount of pooled human IgG is from 300 mg/kg to 800 mg/kg body weight of the subject per two week period, and where the amount is administered in one or more doses during the two week period after initiation of a therapeutic regimen. Also provided, are methods for selecting a treatment regimen for a subject with Alzheimer's disease, including diagnosing the severity of the Alzheimer's disease, determining if the subject carries an APOE4 allele, or both, and assigning a treatment regimen including administration of pooled human immunoglobulin G and/or an anti-beta amyloid monoclonal antibody.

traducir

NON-INVASIVE IMAGING METHOD FOR EARLY DETECTION AND MAPPING THE SEVERITY OF DISEASES

NºPublicación: WO2019084520A1 02/05/2019

Solicitante:

NORTH AMERICA IMAGING DEV LLC [US]

US_2019128981_A1

Resumen de: WO2019084520A1

This invention relates to disease detection by imaging. Previously, there was no way to use CEST MRI imaging to detect and map the accumulation of amyloid beta, neurofibrillary tangles, and aggregation proteins and peptides. Embodiments of the present invention use a non-invasive CEST MRI imaging method is disclosed for early detection and mapping the severity of diseases by using MRI. The endogenous (MRI) contrast of the biological tissue can rely on the endogenous protons of the proteins and peptides as a source of the contrast, such as hydroxyl, amine, and amide protons, and thereby provide imaging of the accumulation of amyloid beta, accumulation of neurofibrillary tangles, aggregation proteins and peptides, the hypoxia in cancer and non-cancer tissue, the tissues atrophy, distinguish the edema from the tumor, determine tumor boundary, monitor response of tumor to treatment and detect lower grade tumor by using endogenous protons contrast via CEST MRI.

traducir

GLUCAGON/GLP-1 RECEPTOR CO-AGONISTS

NºPublicación: US2019127433A1 02/05/2019

Solicitante:

INDIANA UNIV RESEARCH AND TECHNOLOGY CORPORATION [US]

US_2017349642_A1

Resumen de: US2019127433A1

Provided herein are peptides and variant peptides that exhibit enhanced activity at the GLP-1 receptor, as compared to native glucagon.

traducir

BLOOD TEST FOR SCREENING OUT AMYLOID AND ALZHEIMER'S DISEASE PRESENCE

NºPublicación: EP3475707A1 01/05/2019

Solicitante:

UNIV OF NORTH TEXAS HEALTH SCIENCE CENTER AT FORT WORTH [US]

AU_2017281229_A1

Resumen de: WO2017223291A1

The present invention includes a method for excluding patients from the need for further analysis of Alzheimer's Disease comprising: obtaining a blood or serum sample from a patient in a primary care setting; determining the expression levels of at least 4 of the following proteins: FABP, beta 2 microglobulin, PPY, soluble tumor necrosis factor receptor 1 (sTNFRl), CRP, VCAM-1, thrombopoietin, α2 macroglobulin, eotaxin 3, tumor necrosis factor-alpha (TNF-α), tenascin C (TNC), IL-5, IL-6, IL-7, IL-10, IL-18, 1309, Factor VII, thymus and activation-regulated chemokine (TARC), serum amyloid A (SAA), and intercellular cell-adhesion molecule-1 (ICAM-1); comparing the level of expression from the sample with a statistically locked-down, multi-ethnic, broad age spectrum statistical sample; and determining if the patient is excluded from further testing for Alzheimer's Disease, thereby eliminating the need for further testing of the patient.

traducir

IN VITRO DIAGNOSTIC METHOD FOR ALZHEIMER'S DISEASE BASED ON THE ALBUMIN REDOX LEVEL IN THE CEREBROSPINAL FLUID

NºPublicación: RU2017137768A 30/04/2019

Solicitante:

\u0413\u0420\u0418\u0424\u041E\u041B\u042C\u0421 \u0423\u041E\u0420\u041B\u0414\u0423\u0410\u0419\u0414 \u041E\u041F\u0415\u0420\u0415\u0419\u0428\u041D\u0421 \u041B\u0418\u041C\u0418\u0422\u0415\u0414

ES_2706539_T3

Resumen de: EP3324188A1

In vitro diagnostic method for Alzheimer's disease, based on the albumin redox level in the cerebrospinal fluid. The present invention relates to an in vitro diagnostic method for diagnosing Alzheimer's disease (AD), comprising the steps of: a) determining the content of mercaptoalbumin (HMA) in a sample of cerebrospinal fluid (CSF); and b) comparing the content determined with the content of HMA in CSF in healthy subjects. If the HMA content is less than that of the healthy subjects, it is indicative of AD. In an embodiment, the HMA level is also determined in blood or plasma and a difference or ratio is calculated.

traducir

Antibody

NºPublicación: RU2017133649A 29/04/2019

Solicitante:

\u041D\u0415\u0419\u0420\u041E-\u0411\u0418\u041E \u041B\u0422\u0414

JP_2018516849_A

Resumen de: GB2541477A

Antibodies for use in the diagnosis and treatment of neurodegenerative disorders, such as Alzheimer's disease and Parkinson's disease. The antibody specifically binds to the T14 peptide or a variant or fragment thereof of acetylcholinesterase (AChE). Also claimed is the use of the T14 peptide as a biomarker for detecting or diagnosing a neurodegenerative disorder and the ex vivo use of a colourimetrically- or fluorescently-labelled T14 peptide for identifying an agent which inhibits T14 peptide synthesis or activity.

traducir

METHOD FOR DETECTING AGGREGATE OF AGGREGATE-FORMING POLYPEPTIDE

NºPublicación: US2019120859A1 25/04/2019

Solicitante:

PEOPLEBIO INC [KR]

CN_108885216_A

Resumen de: US2019120859A1

The present invention relates to a method for detecting an aggregate of an aggregate-forming polypeptide of a biosample, comprising (a) a step of spiking a dimer type of the aggregate-forming polypeptide into the biosample to be analyzed; (b) a step of incubating a resultant product of step (a) to further form an aggregate of the aggregate-forming polypeptide; (c) a step of contacting a resultant product of step (b) with a binding agent-tag in which a signal-generating tag is bound to a binding agent that binds to the aggregate of the aggregate-forming polypeptide; and (d) a step of detecting a signal which is generated from the binding agent-tag bound to the aggregate of the aggregate-forming polypeptide

traducir

COMBINATORIAL SYNTHESIS AND BIOMARKER DEVELOPMENT

NºPublicación: US2019113521A1 18/04/2019

Solicitante:

MOOLA MURALIDHAR REDDY [US]

CN_109641935_A

Resumen de: US2019113521A1

Provided herein are methods, kits, and compositions for use in the diagnosis and treatment of diseases. Peptoids recognized by Alzheimer s disease specific antibodies are identified.

traducir

ASSAY FOR THE DIAGNOSIS OF A NEUROLOGICAL DISEASE

NºPublicación: US2019113527A1 18/04/2019

Solicitante:

EUROIMMUN MEDIZINISCHE LABORDIAGNOSTIKA AG [DE]

CN_109073661_A

Resumen de: US2019113527A1

A diagnostically useful carrier can include a means for capturing Neurogranin, a means for capturing BACE1 and preferably a means for capturing one or more additional biomarkers. The diagnostically useful carrier can be part of a kit. The kit or the carrier can be used in contacting a sample from a subject with a means for capturing Neurogranin, isolating the means for capturing Neurogranin from the sample, contacting a sample from a subject with a means for capturing BACE1, and isolating the means for capturing BACE1 from the sample. The diagnosis aims to distinguish a neurodegenerative disease, preferably mild Alzheimer's disease, and depression with or without cognitive impairment.

traducir

ANTI-TAU ANTIBODIES AND METHODS OF USE

NºPublicación: US2019112362A1 18/04/2019

Solicitante:

GENENTECH INC [US]
AC IMMUNE SA [CH]

US_2019112361_A1

Resumen de: US2019112362A1

The invention provides anti-Tau antibodies and methods of using the same.

traducir

ANTI-TAU ANTIBODIES AND METHODS OF USE

NºPublicación: US2019112361A1 18/04/2019

Solicitante:

GENENTECH INC [US]
AC IMMUNE SA [CH]

US_2019112362_A1

Resumen de: US2019112361A1

The invention provides anti-Tau antibodies and methods of using the same.

traducir

DIAGNOSTIC MARKER FOR DEMENTIA AND METHOD FOR IDENTIFYING CONTRACTION OF DEMENTIA USING SAID MARKER

Nº publicación: US2019113528A1 18/04/2019

Solicitante:

HASHIMOTO YASUHIRO [JP]
FUKUSHIMA MEDICAL UNIV [JP]

JP_WO2017195778_A1

Resumen de: US2019113528A1

An object of the present invention is to develop a biomarker for discriminating dementia, particularly, Alzheimer's disease and mild cognitive impairment which can progress to Alzheimer's disease, from other central nervous system diseases, or capable of determining a pathological condition of dementia, and provide a method for diagnosing dementia early and a method for determining a pathological condition of dementia, using the biomarker. A transferrin glycoprotein containing a glycan having at least one mannose at a non-reducing end or a transferrin fragment containing the glycan is used as a diagnostic marker for Alzheimer's disease.

traducir

Página1 de 2 nextPage por página

punteroimgVolver